TIDMFARN
RNS Number : 7146B
Faron Pharmaceuticals Oy
14 June 2021
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Bexmarilimab granted key US patent
Company announcement, 14 June 2021 at 9.00 AM (EEST)
TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First
North: FARON), the clinical stage biopharmaceutical company, today
announces that the United States Patent and Trademark Office has
granted a new US Patent, No. 11,046,761, with claims protecting the
composition of matter of bexmarilimab. The patent will be issued on
29 June, 2021.
Faron's wholly-owned novel precision cancer immunotherapy drug
candidate, bexmarilimab, targets the Clever-1 receptor, known to be
expressed on immunosuppressive macrophages in the tumour
microenvironment and circulating in soluble form, and which is
capable of directly inhibiting T-cell activation. The reprogramming
of these Clever-1 positive macrophages by bexmarilimab, from an
immunosuppressive state to an immune-stimulating one, is believed
to be a key immune defence against tumour growth and spread.
Bexmarilimab is currently being investigated in the ongoing
Phase I/II MATINS trial as a potential monotherapy in patients with
solid tumours who have exhausted all treatment options. Latest data
from the trial have shown strong initial safety and tolerability,
and promising anti-tumour activity in several refractory metastatic
solid tumours - cutaneous melanoma, gastric cancer and
cholangiocarcinoma.
The US composition of matter patent covers bexmarilimab's
binding sequences and Clever-1's corresponding epitope - specific
elements of the antibody-antigen binding site. The expiry date, not
including any potential extensions, is expected to be 2037.
The same patent has been granted in Japan and applications are
under review in other key territories including Europe and
China.
Dr. Markku Jalkanen, Faron's CEO, said: "We are extremely
pleased to receive this key patent approval which grants us market
exclusivity up to 2037. This patent protection applies specifically
to the binding process between bexmarilimab and its target, the
Clever-1 receptor found on the surface of tumour associated
macrophages in the tumour microenvironment. This novel binding is
key to the conversion of these highly immunosuppressive macrophages
to immune-stimulating ones that can target difficult-to-treat
cancers, and key to the removal of soluble Clever-1 from remote
locations, where it can prevent activation of immune cells. The
patent is a welcome addition to our existing global IP portfolio
for targeting Clever-1 and further strengthens the long-term
potential of this next-generation macrophage reprogramming
immunotherapy."
For more information please contact:
Faron Pharmaceuticals Oy
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Peel Hunt LLP, Broker
Dr Christopher Golden, James Steel
Phone: + 44 (0)20 7418 8900
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone. +44 (0)20 7213 0880
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 55 38 990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Stern Investor Relations
Julie Seidel
Phone: +1 212 362 1200
Email: julie.seidel@sternir.com
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. The Company currently has a pipeline based on
the receptors involved in regulation of immune response in
oncology, organ damage and bone marrow regeneration. Bexmarilimab,
a novel anti-Clever-1 humanised antibody, is its investigative
precision immunotherapy with the potential to provide permanent
immune stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with untreatable solid tumours,
bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. Traumakine is an investigational intravenous
(IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine is currently being
evaluated in global trials as a potential treatment for
hospitalised patients with COVID-19 and with the 59th Medical Wing
of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma. Faron is
based in Turku, Finland. Further information is available at
www.faron.com .
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identified by their use of terms and phrases such as "believe",
"could", "should", "expect", "hope", "seek", "envisage",
"estimate", "intend", "may", "plan", "potentially", "will" or the
negative of those, variations or comparable expressions, including
references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other
expenditures (including the amount, nature and sources of funding
thereof), competitive advantages, business prospects and
opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on
information currently available to the Directors.
A number of factors could cause actual results to differ
materially from the results and expectations discussed in the
forward-looking statements, many of which are beyond the control of
the Company. In particular, the early data from initial patients in
the MATINS trial may not be replicated in larger patient numbers
and the outcome of clinical trials may not be favourable or
clinical trials over and above those currently planned may be
required before the Company is able to apply for marketing approval
for a product. In addition, other factors which could cause actual
results to differ materially include the ability of the Company to
successfully licence its programmes within the anticipated
timeframe or at all, risks associated with vulnerability to general
economic and business conditions, competition, environmental and
other regulatory changes, actions by governmental authorities, the
availability of capital markets or other sources of funding,
reliance on key personnel, uninsured and underinsured losses and
other factors. Although any forward-looking statements contained in
this announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward looking
statements. Accordingly, readers are cautioned not to place undue
reliance on forward looking statements. Subject to any continuing
obligations under applicable law or any relevant AIM Rule
requirements, in providing this information the Company does not
undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events,
conditions or circumstances on which any such statement is
based.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFJMATMTTBBRB
(END) Dow Jones Newswires
June 14, 2021 02:00 ET (06:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2023 to Apr 2024